ATE551329T1 - Chinazolinonderivate und deren verwendung als cb- agonisten - Google Patents

Chinazolinonderivate und deren verwendung als cb- agonisten

Info

Publication number
ATE551329T1
ATE551329T1 AT03737316T AT03737316T ATE551329T1 AT E551329 T1 ATE551329 T1 AT E551329T1 AT 03737316 T AT03737316 T AT 03737316T AT 03737316 T AT03737316 T AT 03737316T AT E551329 T1 ATE551329 T1 AT E551329T1
Authority
AT
Austria
Prior art keywords
agonists
quinazolinone derivatives
quinazolinone
derivatives
Prior art date
Application number
AT03737316T
Other languages
English (en)
Inventor
Christopher Brain
Edward Dziadulewicz
Terance Hart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202755A external-priority patent/GB0202755D0/en
Priority claimed from GB0213285A external-priority patent/GB0213285D0/en
Priority claimed from GB0221459A external-priority patent/GB0221459D0/en
Priority claimed from GB0221460A external-priority patent/GB0221460D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE551329T1 publication Critical patent/ATE551329T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03737316T 2002-02-06 2003-02-05 Chinazolinonderivate und deren verwendung als cb- agonisten ATE551329T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0202755A GB0202755D0 (en) 2002-02-06 2002-02-06 Organic compounds
GB0213285A GB0213285D0 (en) 2002-06-10 2002-06-10 Organic compound
GB0221459A GB0221459D0 (en) 2002-09-16 2002-09-16 Organic compound
GB0221460A GB0221460D0 (en) 2002-09-16 2002-09-16 Organic compound
PCT/EP2003/001140 WO2003066603A1 (en) 2002-02-06 2003-02-05 Quinazolinone derivatives and their use as cb agonists

Publications (1)

Publication Number Publication Date
ATE551329T1 true ATE551329T1 (de) 2012-04-15

Family

ID=27739227

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03737316T ATE551329T1 (de) 2002-02-06 2003-02-05 Chinazolinonderivate und deren verwendung als cb- agonisten

Country Status (21)

Country Link
US (2) US20050085493A1 (de)
EP (2) EP2319839A1 (de)
JP (2) JP4428479B2 (de)
KR (1) KR100954626B1 (de)
CN (1) CN100579968C (de)
AR (1) AR038483A1 (de)
AT (1) ATE551329T1 (de)
AU (1) AU2003210212A1 (de)
BR (1) BR0307461A (de)
CA (1) CA2471974C (de)
CO (1) CO5601021A2 (de)
EC (1) ECSP045219A (de)
ES (1) ES2384967T3 (de)
MX (1) MXPA04007641A (de)
MY (1) MY143958A (de)
NO (1) NO328305B1 (de)
NZ (1) NZ571615A (de)
PE (1) PE20030867A1 (de)
PL (1) PL370657A1 (de)
TW (1) TW200306839A (de)
WO (1) WO2003066603A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514195A (en) 1999-03-17 2004-05-28 Astrazeneca Ab Amide derivatives
TW200306839A (en) * 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
DE602004024814D1 (de) 2003-11-04 2010-02-04 Merck & Co Inc Substituierte naphthyridinonderivate
SE0303491D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
CN100506802C (zh) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 一类甲酰肽样受体-1调节剂、其制备方法和用途
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds
AU2006268680B2 (en) * 2005-07-11 2012-11-22 Msd Oss B.V. Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
FR2944013B1 (fr) * 2009-04-07 2011-07-15 Sanofi Aventis Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique.
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CN106146414A (zh) * 2016-07-07 2016-11-23 浙江大学 喹唑啉二酮类衍生物及其制备方法和用途
CN106831502A (zh) * 2017-03-13 2017-06-13 苏州市泽宸贸易有限公司 邻硝基苯磺酰氯、其合成方法及应用
CN109796360B (zh) * 2019-01-30 2022-03-18 上海阿拉丁生化科技股份有限公司 一种3-氨基-2-萘甲酸类化合物的制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6200M (de) 1967-04-18 1968-07-22
DE1803210A1 (de) 1968-10-16 1970-05-14 Troponwerke Dinklage & Co 2-Methyl-3-(3-[4-phenylpiperazinyl-(1)]-2-hydroxypropyl)-chinazolinon-(4) und Verfahren zu seiner Herstellung
NZ192392A (en) * 1978-12-19 1983-02-15 M Ishikawa 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones
JPS5657768A (en) * 1979-10-18 1981-05-20 Masayuki Ishikawa Novel 4-quinazolone derivative substituted by aromatic residue at 3-position
JPS57118570A (en) * 1981-01-16 1982-07-23 Masayuki Ishikawa Novel 3-phenyl-4-quinazolone derivative
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
AU4246793A (en) * 1992-05-13 1993-12-13 Alcon Laboratories, Inc. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
AU1618697A (en) * 1996-02-06 1997-08-28 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
TW200306839A (en) * 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
SE0303491D0 (sv) 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
NZ571615A (en) 2010-01-29
TW200306839A (en) 2003-12-01
CA2471974C (en) 2011-11-22
ES2384967T3 (es) 2012-07-16
KR100954626B1 (ko) 2010-04-27
AR038483A1 (es) 2005-01-19
JP2005522439A (ja) 2005-07-28
US20070265285A1 (en) 2007-11-15
CN100579968C (zh) 2010-01-13
NO20043580D0 (no) 2004-08-27
CN1628104A (zh) 2005-06-15
WO2003066603A1 (en) 2003-08-14
CA2471974A1 (en) 2003-08-14
HK1079518A1 (zh) 2006-04-07
CO5601021A2 (es) 2006-01-31
EP1472234A1 (de) 2004-11-03
US20050085493A1 (en) 2005-04-21
NO328305B1 (no) 2010-01-25
MY143958A (en) 2011-07-29
EP1472234B1 (de) 2012-03-28
AU2003210212A1 (en) 2003-09-02
JP2009149658A (ja) 2009-07-09
MXPA04007641A (es) 2004-11-10
KR20040083501A (ko) 2004-10-02
PE20030867A1 (es) 2003-12-04
US8552015B2 (en) 2013-10-08
PL370657A1 (en) 2005-05-30
EP2319839A1 (de) 2011-05-11
ECSP045219A (es) 2004-09-28
BR0307461A (pt) 2004-11-09
JP4428479B2 (ja) 2010-03-10
NO20043580L (no) 2004-09-21

Similar Documents

Publication Publication Date Title
ATE551329T1 (de) Chinazolinonderivate und deren verwendung als cb- agonisten
DE60325761D1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
ATE394102T1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE602004021037D1 (de) Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
DE60332023D1 (de) Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
ATE395339T1 (de) Biphenylderivate und deren verwendung als fungizide
ATE398108T1 (de) Chinolinderivate und deren verwendung als 5-ht6 liganden
DE60317093D1 (de) Chinolin-; isochinolin- und chinazolinoxyalkylamide und ihre verwendung als fungizide
DE60317348D1 (de) Pyrimidinderivate und deren verwendung als cb2-modulatoren
ATE378338T1 (de) Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten
DE60314600D1 (de) O-cyclopropyl-carboxanilide und ihre verwendung als fungizide
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DE602005004144D1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mitteln
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
DE60321958D1 (de) Indazolderivate und ihre verwendung als crf antagonisten
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE50311397D1 (de) Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren
EP1469860A4 (de) Antikrebskombination und deren verwendung
ATE396185T1 (de) Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
DE50206476D1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
ATE353083T1 (de) Naphthyridin-derivate und ihre verwendung als fungizide
ATE517098T1 (de) Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
ATE413387T1 (de) Substituierte pyridyloxyalkylamide und ihre verwendung als fungizide
DE50313185D1 (de) 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva